HK Stock Market Move | JXR (01951) rose by over 4% as of the end of February, with rapid growth in its business data in Shenzhen and the United States.

JXR (01951) rose by more than 4%, as of the time of writing, it rose by 4.15% to 2.51 Hong Kong dollars, with a turnover of 89.3858 million Hong Kong dollars. In terms of news, JXR recently disclosed that as of the end of February 2026, its Shenzhen and U.S. business segments have shown rapid growth in business data, continuing and strengthening the trend of performance improvement since the second half of 2025. In particular, the new area of Shenzhen Zhongshan Maternity Hospital began trial operation on February 6, 2026. As of the end of February 2026, the business growth of Shenzhen Zhongshan Maternity Hospital is strong, with a year-on-year increase of 18% in the egg retrieval cycle; in the U.S. region, driven by the implementation of the "SB729" bill, as of the end of February 2026, HRC Fertility saw a year-on-year increase of 38% in the egg retrieval cycle. Prior research reports from PuYin International pointed out that the company is a leading private assisted reproduction company. With scarce private assisted reproduction licenses and years of experience in the assisted reproduction field, it is expected to continue to win more market share. The bank believes that if the company's business growth in the coming quarters is stronger than expected, there may be a significant opportunity for the company's stock price to rise.